Health Affairs blog, in collaboration with IVI, today launched a new featured topic series titled “Drugs and Medical Innovation.”
As Health Affairs blog editor Chris Fleming notes in an introductory post, the areas of drugs and medical innovation “have long been central in health care and health policy, and recent developments have heightened their importance even more. The US health system has increasingly coalesced around transitioning from payment systems that reward high-volume care to those that reward value in health care services and technology. This has brought to the fore questions about how to evaluate and pay for prescription drugs and other medical technologies in a way that encourages access and innovation, but at the same time is affordable for consumers and public and private payers.” Articles in the blog series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues.
“In the movement toward a value-based—rather than volume-based—healthcare system, the majority of debate around how to appropriately measure value and maximize the benefits generated by medical innovation has centered on drugs and other new technologies,” noted Darius Lakdawalla, Executive Director of IVI. “An open forum for sharing ideas and debating issues in this area is essential. We are excited to partner with Health Affairs blog to extend the discussion to a broader audience.”Read more here.
Viewpoint 9/15/16On the Health Affairs Blog: Goldman, Nussbaum, and Linthicum discuss the need for innovation in pricing and value measurement
In an inaugural post to the Health Affairs blog series on “Drugs and Medical Innovation,” Dana Goldman, Samuel Nussbaum, and Mark Linthicum discuss the need for innovation in pricing and value measurementREAD MORE